buyModerate cluster of 4
Donald William Nicholson bought $144k of GBIO
director at Generation Bio Co.. 100,000 shares at an average of $1.44, traded Dec 1, 2023, filed Dec 5, 2023.
Conviction score
51Value
$144k
100,000 shares
Holdings after
213,576
+88% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +11Trade size$144k at market
- +10Relative to holdingsHoldings up 88%
- 0Price contextNo price history yet
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-23-015856, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 1, 2023 | POpen-market purchase Common Stock | +100,000 | $1.44 | $144k | 213,576 | Dec 5, 2023 |
Related signals
Other insiders at Generation Bio Co. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 37Weak | GBIObuy Generation Bio Co. | Anthony G. Quinn director | $203k 210,791 shares | +238% | |
| 18Weak | Generation Bio Co. | Antoinette Paone CHIEF OPERATING OFFICER | $3,961 2,445 shares | -30% | |
| 3Weak | Generation Bio Co. | Phillip Samayoa CHIEF STRATEGY OFFICER | $3,961 2,445 shares | -2% | |
| 45Moderate | Generation Bio Co. | Dannielle Appelhans director | $14k 8,000 shares | +67% | |
| 38Weak | Generation Bio Co. | Dannielle Appelhans director | $18k 12,000 shares | - | |
| 48Moderate | Generation Bio Co. | Anthony G. Quinn director | $125k 88,495 shares | - | |
| 58Moderate | Generation Bio Co. | Charles A Rowland Jr director | $478k 342,960 shares | +179% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.